Jamieson is pleased to announce that it has advised Chris Paquette and the management team of DeepIntent on their equity incentive arrangements as part of the majority investment in the business by Vitruvian Partners.
Founded in 2016, DeepIntent is the leading healthcare demand-side platform (DSP), purpose-built to help marketers plan, activate, and optimize data-driven campaigns with speed and precision. The company uses real clinical data to help pharma and health brands execute marketing campaigns, giving brands access to a health data marketplace, helping them build out custom audiences of patients and healthcare practitioners, and managing ad buys across channels. The company services some of the top life sciences companies and their advertising agencies globally.
The investment by Vitruvian will help accelerate DeepIntent’s next phase of expansion and product innovation, enhancing its platform with new generative AI capabilities and integrations that improve patient outcomes.
Mark Wasserberger, Ian Rosamilia and Richard Brumpton advised the team on their incentive program and equity participation within the new structure.
Jamieson Corporate Finance US LLC, Member of FINRA/SIPC
